The prostate is part of the male genitourinary tract. It is a walnut-sized gland, located underneath the urinary bladder, enveloping the proximal part of the urethra. The main function of the prostate is the excretion of a fl uid that forms part of the semen, but it also has an important role in controlling the fl ow of semen at the moment of ejaculation. Cancer of the prostate is a major health issue, it is mainly found in elderly men. In the United States, as an example for most Western countries, prostate cancer (PC) is the most frequently diagnosed non-skin cancer and is the second leading cause of cancerrelated mortality in men. A total of 192.280 new cases are estimated to be detected and 27.360 men are estimated to die of this disease in 2009 in the United States1. This means that 1 out of every 6 men will be diagnosed with the disease during their lifetime and 1 out of every 35 will die of it. The impressively high frequency of PC is further illustrated by autopsy studies, which show that as much as 55% of men in their fi fties and 64% of men in their seventies harbour the disease.

PSA, prostate cancer
C.H. Bangma (Chris) , E.W. Steyerberg (Ewout)
Erasmus University Rotterdam
The ERSPC study Europe-wide is supported by Beckman-Coulter-Hybritech Inc.. The Dutch section of the ERSPC is supported by the Dutch Cancer Society; The Netherlands Organization for Health Research and Development (ZonMW). The Swedish section of the ERSPC is supported by Abbot Pharmaceuticals, Sweden; Af Jochnick’s foundation; Catarina and Sven Hagstroms family foundation; Gunvor and Ivan Svensson’s foundation; Johanniterorden; King Gustav V Jubilée Clinic Cancer Research foundation; Sahlgrenska University Hospital; Schering-Plough, Sweden; the Swedish Cancer Society; Wallac Oy, Turkku, Finland. The Finnish section of the ERSPC is supported by the Academy of Finland; the Cancer Society of Finland; the Finnish Cancer Institute; the Medical Research Fund of Tampere University Hospital; the Competitive Research Funding of the Pirkanmaa Hospital District; the Sigrid Juselius foundation; the Pirkanmaa Cancer Society; the Finnish Cultural foundation; Helsinki University Central Hospital Research Funds; the foundation of K. Albin Johansson; the Finska Läkaresällskapet; the Medical Research Fund of Seinäjoki Central Hospital; the Stockman foundation; the Helsingin Sanomat Centenarian foundation; the Europe Against Cancer Program; Perkin Elmer-Wallac; Doctoral Programme in Public Health; Astra Zeneca Group and Pharmacia Corporation in support of a PhD thesis. The International coordination of the ERSPC is supported by European Union Grants; the 6th Framework Program of the EU: P-Mark. The PRIAS study is supported by the Prostate Cancer Research foundation (Stichting Wetenschappelijk Onderzoek Prostaatkanker; SWOP) Rotterdam, the Netherlands.
978-90-8559-602-8
hdl.handle.net/1765/17464
Erasmus MC: University Medical Center Rotterdam

van den Bergh, R.C.N. (2009, December 9). Active Surveillance For Low Risk Prostate Cancer. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/17464